Literature DB >> 20887830

The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection.

Nancy F Crum-Cianflone1, Mollie Roediger, Kathy Huppler Hullsiek, Anuradha Ganesan, Michael Landrum, Amy Weintrob, Brian Agan, Sheila Medina, Jeremy Rahkola, Braden Hale, Edward N Janoff.   

Abstract

Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (≥2-fold rise in capsule-specific IgG from baseline with post-vaccination value ≥1 μg/mL for ≥2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p=0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887830      PMCID: PMC2981674          DOI: 10.1016/j.vaccine.2010.09.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.

Authors:  R F Breiman; D W Keller; M A Phelan; D H Sniadack; D S Stephens; D Rimland; M M Farley; A Schuchat; A L Reingold
Journal:  Arch Intern Med       Date:  2000-09-25

2.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.

Authors:  M S Dworkin; J W Ward; D L Hanson; J L Jones; J E Kaplan
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

5.  Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses.

Authors:  Sybil A Tasker; Mark R Wallace; Jeffrey B Rubins; William B Paxton; James O'Brien; Edward N Janoff
Journal:  Clin Infect Dis       Date:  2002-02-07       Impact factor: 9.079

6.  A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Mollie Roediger; Anuradha Ganesan; Sugat Patel; Michael L Landrum; Amy Weintrob; Brian K Agan; Sheila Medina; Jeremy Rahkola; Braden R Hale; Edward N Janoff
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

7.  Pneumococcal bacteremia in Charleston County, South Carolina.

Authors:  G A Filice; C P Darby; D W Fraser
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

8.  A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.

Authors:  Neil French; Michael Moore; Raili Haikala; Helena Kayhty; Charles F Gilks
Journal:  J Infect Dis       Date:  2004-07-16       Impact factor: 5.226

9.  Pneumococcal bacteremia in Charleston County, South Carolina. A decade later.

Authors:  R F Breiman; J S Spika; V J Navarro; P M Darden; C P Darby
Journal:  Arch Intern Med       Date:  1990-07

Review 10.  Global strategies to prevent bacterial pneumonia in adults with HIV disease.

Authors:  Daniel R Feikin; Charles Feldman; Anne Schuchat; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

View more
  5 in total

1.  Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency.

Authors:  F M Cavaliere; C Milito; H Martini; M Schlesier; R Dräger; K Schütz; G Brunetti; A M Pesce; V Thon; K Warnatz; I Quinti
Journal:  J Clin Immunol       Date:  2012-12-29       Impact factor: 8.317

2.  Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.

Authors:  Myroslawa Happe; Devadoss J Samuvel; Jennifer A Ohtola; Jeff E Korte; M A Julie Westerink
Journal:  Vaccine       Date:  2019-02-21       Impact factor: 3.641

3.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

4.  Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination.

Authors:  A-L Munier; V de Lastours; E Varon; J-L Donay; R Porcher; J-M Molina
Journal:  Infection       Date:  2013-02-13       Impact factor: 3.553

5.  The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study.

Authors:  Reed A C Siemieniuk; Dan B Gregson; M John Gill
Journal:  BMC Infect Dis       Date:  2011-11-11       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.